Clovis Stock Analysis

CLVS
 Stock
  

USD 1.05  0.07  6.25%   

The latest Clovis Oncology price fall could raise concerns from retail investors as the firm is trading at a share price of 1.05 on 1,401,384 in volume. The company management teams were unable to exploit market volatilities in August. However, diversifying your overall positions with Clovis Oncology can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 11.03. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Clovis Oncology partners.
Continue to Trending Equities.
  
The Clovis Oncology stock analysis report makes it easy to digest most publicly released information about Clovis Oncology and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Clovis Stock analysis module also helps to analyze the Clovis Oncology price relationship with some important fundamental indicators such as market cap and management efficiency.

Clovis Stock Analysis Notes

About 40.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 4.38. Clovis Oncology had not issued any dividends in recent years. Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people. For more info on Clovis Oncology please contact Patrick Mahaffy at 303 625 5000 or go to https://www.clovisoncology.com.

Clovis Oncology Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Clovis Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Clovis Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Clovis Oncology generated a negative expected return over the last 90 days
Clovis Oncology has high historical volatility and very poor performance
Clovis Oncology has some characteristics of a very speculative penny stock
Clovis Oncology has a very high chance of going through financial distress in the upcoming years
Clovis Oncology has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 144.95 M. Net Loss for the year was (258.42 M) with profit before overhead, payroll, taxes, and interest of 115.3 M.
Clovis Oncology currently holds about 122.24 M in cash with (192.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85.
Latest headline from MacroaxisInsider: Sale by Paul Gross of 2062 shares of Clovis Oncology

Clovis Oncology Upcoming and Recent Events

Earnings reports are used by Clovis Oncology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Clovis Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Clovis Oncology SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Clovis Oncology prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Clovis Oncology investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Clovis Oncology specific information freely available to individual and institutional investors to make a timely investment decision.
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
8th of July 2022
Unclassified Corporate Event
View
7th of July 2022
Submission of Matters to a Vote of Security Holders
View
6th of July 2022
Other Events
View
16th of June 2022
Other Events
View
9th of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
11th of April 2022
Unclassified Corporate Event
View

Clovis Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Clovis Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clovis Oncology backward and forwards among themselves. Clovis Oncology's institutional investor refers to the entity that pools money to purchase Clovis Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Antara Capital LpDebt80.1 M57.3 M
Vanguard Group IncCommon Shares11.2 M20.2 M
Millennium Management LlcCommon Shares5.4 M9.7 M
Blackrock IncCommon Shares4.7 M8.5 M
Palo Alto Investors LpCommon Shares4.5 M8.1 M
Antara Capital LpPut OptionsM5.4 M
Renaissance Technologies LlcCommon Shares2.3 M4.1 M
Antara Capital LpCall Options2.2 MM
Qvt Financial LpCommon Shares2.1 M3.8 M
Note, although Clovis Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Clovis Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 136.48 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Clovis Oncology's market, we take the total number of its shares issued and multiply it by Clovis Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Clovis Profitablity

Clovis Oncology's profitability indicators refer to fundamental financial ratios that showcase Clovis Oncology's ability to generate income relative to its revenue or operating costs. If, let's say, Clovis Oncology is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Clovis Oncology's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Clovis Oncology's profitability requires more research than a typical breakdown of Clovis Oncology's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (178.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (146.49) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.46.

Management Efficiency

The entity has return on total asset (ROA) of (26.53) % which means that it has lost $26.53 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 7.97 %, meaning that it created $7.97 on every $100 dollars invested by stockholders. Clovis Oncology management efficiency ratios could be used to measure how well clovis oncology manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Clovis Oncology shows the risk adjusted performance of (0.020835), and Mean Deviation of 6.06. Clovis Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Clovis Oncology, which can be compared to its rivals. Please confirm Clovis Oncology coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Clovis Oncology is priced correctly, providing market reflects its regular price of 1.05 per share. Given that Clovis Oncology is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Clovis Oncology Price Movement Analysis

The output start index for this execution was thirty-four with a total number of output elements of twenty-seven. The Weighted Moving Average calculates a weight for each value in Clovis Oncology price series with the more recent values given greater weights.
.

Clovis Oncology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clovis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clovis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clovis Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Paul Gross few days ago via Macroaxis 
Sale by Paul Gross of 2062 shares of Clovis Oncology
Harding Thomas C over two weeks ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 508 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three weeks ago via Macroaxis 
Sale by Harding Thomas C of 172 shares of Clovis Oncology
Harding Thomas C over a month ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 181 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over two months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of tradable shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over two months ago via Macroaxis 
Sale by Harding Thomas C of tradable shares of Clovis Oncology
Harding Thomas C over three months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 507 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 181 shares of Clovis Oncology subject to Rule 16b-3
Daniel Muehl over three months ago via Macroaxis 
Exercise or conversion by Daniel Muehl of 4625 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of tradable shares of Clovis Oncology subject to Rule 16b-3
Daniel Muehl over six months ago via Macroaxis 
Sale by Daniel Muehl of 290 shares of Clovis Oncology
Gillian IversRead over six months ago via Macroaxis 
Sale by Gillian IversRead of 1989 shares of Clovis Oncology

Clovis Oncology Predictive Daily Indicators

Clovis Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Clovis Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Clovis Oncology Forecast Models

Clovis Oncology time-series forecasting models is one of many Clovis Oncology's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Clovis Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Clovis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Clovis Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Clovis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Clovis Oncology. By using and applying Clovis Stock analysis, traders can create a robust methodology for identifying Clovis entry and exit points for their positions.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people.

Current Clovis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Clovis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Clovis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Hold2Odds
Clovis Oncology current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Clovis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Clovis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Clovis Oncology, talking to its executives and customers, or listening to Clovis conference calls.
Clovis Analyst Advice Details

Clovis Stock Analysis Indicators

Clovis Oncology stock analysis indicators help investors evaluate how Clovis Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Clovis Oncology shares will generate the highest return on investment. By understating and applying Clovis Oncology stock analysis, traders can identify Clovis Oncology position entry and exit signals to maximize returns.
Quick Ratio1.29
Fifty Two Week Low0.5800
Revenue Growth-10.00%
Shares Short Prior Month41.25M
Average Daily Volume Last 10 Day6.61M
Average Daily Volume In Three Month8.23M
Shares Percent Shares Out19.86%
Gross Margins77.06%
Short Percent Of Float20.25%
Forward Price Earnings-1.24
Float Shares141.84M
Fifty Two Week High4.9100
Enterprise Value To Ebitda-3.78
Fifty Day Average1.4382
Two Hundred Day Average1.7851
Enterprise Value To Revenue5.32
Continue to Trending Equities. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Clovis Oncology price analysis, check to measure Clovis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clovis Oncology is operating at the current time. Most of Clovis Oncology's value examination focuses on studying past and present price action to predict the probability of Clovis Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Clovis Oncology's price. Additionally, you may evaluate how the addition of Clovis Oncology to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Is Clovis Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clovis Oncology. If investors know Clovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clovis Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Clovis Oncology is measured differently than its book value, which is the value of Clovis that is recorded on the company's balance sheet. Investors also form their own opinion of Clovis Oncology's value that differs from its market value or its book value, called intrinsic value, which is Clovis Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clovis Oncology's market value can be influenced by many factors that don't directly affect Clovis Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clovis Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Clovis Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clovis Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.